Skip to content
thestock.space

On 6 Nov 2026, Zydus Lifesciences was priced at ₹1,197.90, or 28.6× trailing earnings, against an industry P/E of 28.7×. Sales and net profit grew 17% and 37% a year over 3 years; its ROCE of 19% is the second-highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.46× equity, and its dividend yield is 0.1%. It is a large-cap company with a market cap of ₹1.2 lakh crore, ranked 5th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 23% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹1,194.50
Day high
₹1,207.50
Day low
₹1,190.00
Prev. close
₹1,193.00
Volume
17.1 L

Health check

1 good · 4 fair · 1 to check
  • ReturnsIn line

    +22.8% over a year, better than 4 of 7 peers.

  • Price tagIn line

    P/E 28.6 vs industry 28.7.

  • GrowthStrong

    Sales +16.5%, profit +37.0% a year over 3 years.

  • ProfitabilityAverage

    ROCE 19.0% vs peer median 14.9%.

  • Balance sheetFair

    Debt 0.46× equity, interest covered 19.1×, Piotroski 5 of 9.

  • Red flags1 to check

    Quarterly profit down 35.9% on a year ago.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹1.2L Cr, #5 of 154 in its industry by size.

Defensive

Beta 0.31 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Jun 2026: sales ₹30,378 Cr · profit ₹4,198 Cr
Market cap
₹1.2L Cr
Large cap
P/E
28.6
Industry 28.7
Price to book
4.29
Peers 5.97
Dividend yield
0.08%
ROE
14.7%
Peers 13.6%
ROCE
19.0%
Peers 14.9%
Debt to equity
0.46
Debt ₹13,966 Cr
EPS (TTM)
₹41.85
Face value ₹1
OPM (TTM)
26.2%
Net margin 13.8%
Sales growth
+20.6%
Latest quarter vs a year ago
Profit growth
−35.9%
Latest quarter vs a year ago
Price to sales
3.93
EV/EBITDA 18.3

Strengths and risks

Strengths

  • Quarterly sales up 20.6% on a year ago.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • Quarterly profit down 35.9% on a year ago.

Derived automatically from reported figures. Not a recommendation.

About Zydus Lifesciences

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Consumer Products, and Medical Technologies. The company offers active pharmaceutical ingredients, human and finished dosage formulations, generics, branded generics, specialty formulations, biosimilars,…

Headquarters
Ahmedabad
Employees
29,980
Sector
Healthcare
ISIN
INE010B01027
Website
zyduslife.com

Price range

52 weeks

₹835.50₹1,266.60

Today

₹1,190.00₹1,207.50
Avg volume (3M)
16.5 L
1-year return
plus 22.8%
From 52-week high
minus 5.4%

Analyst consensus

29 analysts
HoldMean target ₹1,224.78 plus 2.2%

Target range, with today’s price

Low ₹800.00High ₹1,457.48

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.87%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.30%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.81%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.59%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.93%minus 6.6%
MANKINDMankind Pharma2,540.00plus 0.87%1,04,91346.85.9713.7%13.6%26.5%17.7%14.3%0.00%plus 6.3%
Median of 7 peers–0.85%1,26,43346.85.9714.9%13.6%28.2%11.0%11.5%0.59%13.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrMar 25Jun 25Dec 25Mar 26Jun 26
6,2906,4676,7807,4347,802
–––+18.2%+20.6%
4,1254,4365,1285,5255,930
2,1652,0311,6521,9101,873
34.4%31.4%24.4%25.7%24.0%
41.2212276779163
76.684.7130123156
238238360508555
−220–−84.9−398−18.2
1,6721,9211,3531,6601,307
25.3%22.6%28.7%19.2%27.1%
1,1711,4671,0421,273940
–––+8.7%minus 35.9%
11.6414.5810.3612.659.35

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+16.5%
Profit CAGR 3Y
+37.0%
EPS CAGR 3Y
+37.4%
ROE
14.7%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
16,87819,02222,57426,720
–+12.7%+18.7%+18.4%
13,30213,71815,67919,525
3,5765,3036,8957,195
21.2%27.9%30.5%26.9%
−2342082181,709
1264493.5365
7237649161,408
96.1106−76.8−510
2,5904,8096,0276,621
22.7%20.3%23.4%24.1%
1,9603,8604,5265,040
–+96.9%+17.3%+11.4%
19.3038.1444.9750.09

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
101101101101
17,41519,72923,85327,011
1,1958043,21312,496
7,0468,64710,03512,799
25,75629,28137,20252,407
6,9737,0497,56010,730
1,2771,2461,5181,499
739449421604
1,2071,3805,6424,971
15,56119,15822,06134,603
25,75629,28137,20252,407

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,6893,1966,7812,117
1,535−1,475−8,358−8,296
−4,400−1,7791,9955,807
−177−57.7419−373
−1,031−907−1,694−2,672
1,6582,2905,087−555
−267−621−303−1,106

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 15.5% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you